SCHEMBL23698605

SCHEMBL23698605

CNCC(=O)OCc1cccnc1N(C)C(=O)OCCl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 5/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ CASP3 P42574 2/20 0.35
▸ SENP8 Q96LD8 2/20 0.35
▸ SENP7 Q9BQF6 2/20 0.35
▸ SENP6 Q9GZR1 2/20 0.35
▸ L3MBTL1 Q9Y468 3/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ LMNA P02545 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KMT2A Q03164 3/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22651234 0.90 RAB9A (0.38) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL24496166 0.90 KCNH2 (0.36) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL24604442 0.88 RAB9A (0.36) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL23084629 0.87 CHRM2 (0.34) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL22651406 0.87 ELANE (0.38) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL23061476 0.86 HTT (0.37) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL17485425 0.85 RAB9A (0.39) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL24604432 0.85 NPC1 (0.35) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL22650959 0.84 NPC1 (0.36) HTTALDH1A1CASP3SENP8SENP7
SCHEMBL23698705 0.83 ALDH1A1 (0.35) HTTALDH1A1CASP3SENP8SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152048-B2 Nitroxoline prodrug and use thereof JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-11-26 — — US disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 — — US disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 — — EP disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152048-B2 Nitroxoline prodrug and use thereof NOS1, NOS2, NNT HTT 4191/4885ALDH1A1 706/4885CASP3 621/4885
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF NOS1, NOS2, NNT HTT 4191/4885ALDH1A1 706/4885CASP3 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback